Table 1.
Clinical characteristics of the 301 adolescents after the second COVID-19 vaccination.
| Characteristic | Overall (n = 301) | 13–15 y (n = 207) | 16–18 y (n = 94) | p-Value |
|---|---|---|---|---|
| Age, y | 15 ± 1.6 | 14 ± 0.8 | 17 ± 0.7 | - |
| BMI (kg/m2) | 21 ± 5.0 | 20 ± 4.8 | 22 ± 5.2 | 0.017 |
| Male sex, n (%) | 202 (67.1) | 110 (53.1) | 92 (97.9) | <0.0001 * |
| Underlying disease n (%) | 44 (14.6) | 31 (15.0) | 13 (13.8) | 0.795 |
| Allergic rhinitis | 24 (8.0) | 17 (8.2) | 7 (7.4) | 0.813 |
| Asthma | 7 (2.3) | 5 (2.4) | 2 (2.1) | 0.869 |
| Thalassemia trait | 5 (1.7) | 3 (1.4) | 2 (2.1) | 0.688 |
| G6PD deficiency | 4 (1.3) | 3 (1.4) | 1 (1.1) | 0.782 |
| Attention deficit | 1 (0.3) | 1 (0.5) | 0 | 0.500 |
| Epilepsy | 1 (0.3) | 1 (0.5) | 0 | 0.500 |
| Migraine | 1 (0.3) | 1 (0.5) | 0 | 0.500 |
| Thyrotoxicosis | 1 (0.3) | 0 | 1 (1.1) | 0.500 |
| Symptoms, n (%) | ||||
| Fever | 50 (16.6) | 30 (14.5) | 20 (21.3) | 0.093 |
| Palpitation | 12 (4.0) | 10 (4.8) | 2 (2.1) | 0.268 |
| Chest pain | 8 (2.7) | 5 (2.4) | 3 (3.2) | 0.699 |
| Shortness of breath | 19 (6.3) | 16 (7.7) | 3 (3.2) | 0.134 |
| Headache | 35 (11.6) | 27 (13.0) | 8 (8.5) | 0.257 |
| Laboratory findings | ||||
| Troponin-T, ng/L | 5.6 ± 2.5 | 5.4 ± 2.5 | 5.9 ± 2.5 | 0.112 |
| CK-MB ng/mL | 1.4 ± 0.9 | 1.4 ± 0.9 | 1.5 ± 0.9 | 0.473 |
| Treatment and hospital course | ||||
| NSAIDS, n (%) | 3 (1.0) | 1 (0.5) | 2 (2.1) | 0.178 |
| Hospitalization, n (%) | 2 (0.7) | 0 | 2 (2.1) | 0.035 |
| ICU admission, n (%) | 1 (0.3) | 0 | 1 (1.1) | 0.138 |
* Statistically significant (chi-square test). BMI, body mass index; CK-MB, creatine kinase-myocardial band; NSAIDS, nonsteroidal anti-inflammatory drugs; Trop-T, Troponin-T.